
Myelofibrosis
Ruxolitinib plus navitoclax induced 24-week spleen volume reduction rates twice as high as ruxolitinib plus placebo in MF.
Pelabresib plus ruxolitinib induced significant spleen volume reduction rates without limiting toxicities in myelofibrosis.
Dr. Masarova spoke with HemeToday on findings from a treatment comparison of pacritinib and momelotinib in myelofibrosis.
Treatment using a BET inhibitor as a monotherapy and in combination with appears well-tolerated in myelofibrosis.
Ruben Mesa, MD, spoke at ASCO 2023 about the affect myelofibrosis has on patients’ quality of life.
Zilurgisertib appears safe and well tolerated in patients who have anemia due to myelofibrosis.
A proof-of-concept study indicates the combined use of ruxolitinib and magrolimab is effective in treating myelofibrosis.
The treatment combination of selinexor plus ruxolitinib is effective in treatment-naïve patients with myelofibrosis.
The JAK inhibitor momelotinib appears to have a superior safety profile compared with fedratinib in myelofibrosis.
Patients with myelofibrosis with a certain platelet count who achieve spleen volume reduction on pacritinib have better OS.
Advertisement
Expert Interviews on Hematology
Advertisement